Skip to main content
Download PDF

Erratum: Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats

Diabetology & Metabolic Syndrome volume 7, Article number: 61 (2015) Cite this article

The Original Article was published on 25 September 2014

Erratum

After publication of this manuscript [1], we noted errors to the labels of Fig. 7. The Y-axis of panel C was incorrectly labelled as “Plasma Adiponectin, ng/ml” instead of “PEPCK, % of Vehicle”. (Please see a corrected version of Fig. 7 below).

Fig. 7
figure 1

Impact of timed daily bromocriptine or vehicle administration on gluconeogenic pathway regulators – FOXO1 phosphorylated at Ser256 (Panel a), glucose-6-phosphatase (Panel b), and PEPCK (Panel c). Proteins we quantified by Western blotting. Values are means ± SEM of 8 animals in each group. *Difference is statistically significant; P values are noted under each panel

Full size image

Reference

  1. Ezrokhi M, Luo S, Trubitsyna Y, Cincotta AH. Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats. Diabetol Metab Syndr. 2014;6:104.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. VeroScience LLC, Tiverton, RI, 02878, USA

    Michael Ezrokhi, Shuqin Luo, Yelena Trubitsyna & Anthony H. Cincotta

Authors
  1. Michael Ezrokhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shuqin Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yelena Trubitsyna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anthony H. Cincotta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony H. Cincotta.

Additional information

The online version of the original article can be found under doi:10.1186/1758-5996-6-104.

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ezrokhi, M., Luo, S., Trubitsyna, Y. et al. Erratum: Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats. Diabetol Metab Syndr 7, 61 (2015). https://doi.org/10.1186/s13098-015-0056-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13098-015-0056-x

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us